The Food and Drug Administration (FDA) will be holding
a public meeting in the fall of this year, designed
to gather information about current developments
in uses of nanotechnology materials in FDA regulated
products. In a Federal Register notice displayed
today announcing the meeting, FDA asks that those
interested in presenting at or attending the meeting
inform the agency of their interest.
Nanotechnology is described by the National Nanotechnology
Initiative as the understanding and control of matter
at dimensions of roughly 1 to 100 nanometers, where
unique phenomena enable novel applications. Essentially,
nanotechnology is a branch of science devoted to
the design and production of extremely small matter.
Due to the small size and special properties of
nanotechnology materials, they have great potential
for use in a vast array of FDA-regulated products.
These small materials often have physical or chemical
properties that are different than those of their
larger counterparts Differences include altered magnetic
properties, altered electrical or optical activity,
increased structural integrity, and enhanced chemical
and biological properties.
These differences have the potential to lead to
scientific advances. For example, this technology
could be used to create new drug formulations and
routes of delivery to previously inaccessible sites
in the body.
FDA is holding this meeting to further its understanding
of developments in nanotechnology and, more specifically,
About the new types of nanotechnology products under
development in the areas of foods (including dietary
supplements), food and color additives, animal feeds,
cosmetics, human and animal drugs and human biologics
and medical devices;
About any specific scientific issues related to
the development of these products relevant to FDA's
regulation of them;
Any other issues about which regulated industry,
academia, and the interested public may wish to inform
FDA concerning the use of nanotechnology in FDA-regulated
If there are opportunities for the agency to address
hurdles that may be inhibiting the use of nanotechnology
in medical product development.
While the agency is not accepting registrations
at this time, it would appreciate receiving expressions
of interest from those intending to attend or present
at the meeting. This information will help FDA prepare
and plan for this meeting. Information can be provided
to Poppy Kendall at Poppy.Kendall@FDA.HHS.GOV ,
or 301-827-3360. Based on the level of response,
FDA will obtain a venue and structure the meeting
to accommodate the audience and range of topics discussed.
Details about the venue, specific date, time, and
registration will be provided in a Federal Register
notice closer to the meeting. You may also look for
updates at www.fda.gov/nanotechnology .
Comments may be submitted electronically at http://www.accessdata.fda.gov/scripts/oc/dockets/comments/getDocketInfo.cfm?
mailed to the Division of Dockets Management (HFA),
Food and Drug Administration, 5630 Fishers Lane,
Room 1061, Rockville, MD 20852. All comments should
be identified with Docket Number 2006N-0107.